Stocks Conclude The Week On A Softer Note Friday, July 11, 2025 – ( $BTC $MCD $NVDA $TSLA Rise!)

By John F. Heerdink, Jr.

The U.S. equity markets concluded the week on a softer note, with all major indices retreating from their record highs. The S&P 500 slipped 0.3% to close at 6,259.75, while the Dow Jones Industrial Average declined by 279.13 points, or 0.6%, ending at 44,371.51. The Nasdaq Composite edged down 0.2% to 20,585.53, maintaining its position near historic levels. The Russell 2000 underperformed, falling 0.6% as small-cap stocks faced renewed selling pressure.

Today’s macroeconomic landscape was shaped by anticipation of next week’s key inflation data. Markets digested the latest signals from June’s Consumer Price Index forecasts, which suggest inflation is ticking higher, driven by the early impact of new tariffs. Analysts expect a 0.23% monthly and 2.6% annual increase in headline CPI, with core inflation projected at 0.30% month-over-month and 3.0% year-over-year. The Federal Reserve held interest rates steady, awaiting further clarity on the inflation trajectory and the economic impact of tariffs. Bond markets are currently pricing in a 60% probability of a rate cut in September.

: Closed at 6,259.75, down 0.3%. Nine of eleven sectors finished in the red, with Real Estate and Consumer Discretionary showing relative strength. Market breadth remains narrow, with only two stocks reaching new 52-week highs.
: Ended at 44,371.51, a 0.6% decline. Most components traded lower, reflecting broad-based weakness in blue chips.
: Finished at 20,585.53, down 0.2%. The index remains resilient, buoyed by continued strength in large-cap technology stocks despite sector rotation.
: Fell 0.6%, with small caps lagging amid concerns about growth and higher borrowing costs.

NVIDIA shares advanced 0.93% to $165.63, as the company celebrated its historic $4 trillion market capitalization milestone. The stock’s ascent is underpinned by robust demand for artificial intelligence chips and the impending launch of the Blackwell Ultra series. Analysts remain bullish on NVIDIA’s growth prospects, citing expanding data center revenues and strategic AI partnerships.

Tesla’s stock was subdued, reflecting a cautious outlook from Wall Street, but swung up +1.17% to close at $313.51 on Friday. The company announced plans to open its first showroom in Mumbai, India, on July 15. However, sentiment was tempered by ongoing concerns about slowing EV sales and the potential reduction of government subsidies. Analysts maintain a “Hold” rating, with an average price target suggesting limited near-term upside.

Meta’s share price was modestly lower closing at $717.51, -1.34% as investors digested recent regulatory developments and awaited the company’s upcoming earnings report. No major corporate news was reported today, but the stock continues to trade near its all-time highs, supported by strong advertising revenue and AI-driven product innovation.

McDonald’s shares closed at $299.91, +.51% on Friday. The company remains focused on international expansion and digital transformation, though no significant news emerged today.

Oracle’s stock traded lower in line with the technology sector today closing at $230.56, -1.89% on Friday. Investors are monitoring the company’s cloud growth trajectory and recent partnership announcements, but no material updates were released during today’s session.

Palantir’s shares were little changed closing at $142.10, with the company maintaining investor attention ahead of its next earnings release. The market continues to watch for developments in government contracts and commercial AI adoption.

Rio Tinto’s U.S.-listed shares rose 1.66% to close at $61.10 as commodity prices softened and global trade uncertainties persisted. The mining giant faces headwinds from tariff-related disruptions and fluctuating demand for industrial metals.

No major mergers, acquisitions, or buyouts involving S&P 500 constituents were announced today. IPO activity on the NYSE and Nasdaq remained muted, with no significant new listings or filings reported, reflecting a cautious environment amid ongoing market volatility and tariff uncertainty.

Trade policy remained in focus as the White House reaffirmed plans to implement a 50% tariff on copper imports from Brazil and additional restrictions on Chinese e-commerce platforms, effective August 1. While the market reaction was measured, the prospect of higher tariffs is beginning to filter into inflation expectations and business sentiment. The yield curve flattened further, with shorter-term yields rising on inflation concerns, while longer-term yields held steady as investors anticipate potential Fed easing later in the year.

The Federal Open Market Committee did not issue new policy changes today. The Fed continues to signal a data-dependent approach, with markets increasingly betting on a rate cut in September should inflation remain contained and growth moderate.

: Ended the session marginally higher at $3,370.30/oz, supported by safe-haven demand amid tariff uncertainty.
: Traded higher at $39.08/oz., reflecting mixed signals from industrial demand.
: Prices rose +3.01% to close at $67.35/bbl, with traders weighing global supply dynamics against slowing economic growth.
: Closed near $117,435.44 after hitting a record high of $118,731 a new all-time high on Friday.

Vista Partners Watchlist Highlights & Updates

Eupraxia Pharmaceuticals (EPRX) is clinical-stage biotechnology firm headquartered in Victoria, Canada, has quietly become one of the more intriguing stories on both sides of the border in 2025. The company’s shares now trade under the ticker EPRX on both the Nasdaq and the Toronto Stock Exchange, following its U.S. market debut in April 2024. This dual listing has broadened its investor base at a time when the company’s clinical and financial narrative is gaining momentum. All covering analysts currently rate the stock as a “Buy” or better, with not a single “Hold” or “Sell” recommendation in sight. In a sector defined by binary outcomes and frequent disappointment, such unanimity is striking. Overall, analysts cite Eupraxia’s strong clinical pipeline and revenue growth potential as key drivers behind their bullish outlook.

HC Wainwright: Initiated Covrage on EPRX with a “Strong Buy” on June 26, 2025.
Canaccord Genuity: Initiated coverage with a “Speculative Buy” rating in June 2025.
Raymond James Ltd.: Maintains a “Strong Buy” rating as of June 2025, with a history of upgrades from “Outperform” to “Strong Buy” over the past year.
Research Capital Corporation: Maintains a “Buy” rating, consistently reaffirming its positive stance throughout 2024 and 2025.

Eupraxia announced on July 8 that the first patient dosed in their Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis (“EoE”). EP-104GI is injected directly into the affected tissues of the esophagus to reduce inflammation with stable, localized, and long-duration drug delivery, while minimizing unwanted systemic adverse events and side effects often associated with steroid-based therapies. The Phase 2b portion of the RESOLVE study will enroll a minimum of 60 participants randomized in a 1:1:1 ratio to receive one of two doses of EP-104GI or placebo. After six months, eligible patients initially dosed with placebo may elect to receive EP-104GI. The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”). Secondary and exploratory objectives include evaluating symptomatic improvement through patient-reported outcomes — Straumann Dysphagia Index score (SDI) and Dysphagia Symptom Questionnaire (DSQ), endoscopic and histologic changes (including Peak Eosinophil Count, “PEC”), pharmacokinetics, safety, and tolerability of the selected dose regimens. Up to 25 sites globally are expected to participate in the trial.The Phase 2b portion of the study employs an innovative adaptive design to select the doses of EP-104GI that are administered to patients. The first active dose selection was based on available data from cohorts 1 to 8 of the Phase 2a portion of the study. Based on the previously reported safety, pharmacokinetic, and efficacy data from cohorts 1 to 6, and additional one month data from cohorts 7 and 8, the 120 mg dose (20 injections of 6 mg per site) from cohort 8 was selected for the first treatment arm in the dose optimization phase. A second dose will be selected for evaluation after enrollment in the first arm is complete, based on additional long-term data from the Phase 2a portion of the study. James Helliwell, CEO of Eupraxia Pharmaceuticals stated, “Entering into the Phase 2b stage of the RESOLVE trial is a significant event for Eupraxia. This is an important step for us before proceeding towards the pivotal trials necessary for submitting an application for regulatory approval. We are optimistic that EP-104GI has the potential to significantly advance the standard of care and offer a meaningful new treatment paradigm for patients living with EoE.”

Tribe Public hosted a CEO Presentation and Q&A Webinar Event on Wednesday, May 14th with James A. Helliwell, Director and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX). The event is titled “Hard To Swallow: An Underdiagnosed Condition Rising To Surface (EOE).” You may view it now at https://youtu.be/tCtY_27EJG4?si=0PJIp-oyGDEpzxzR

Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit announced (May 30) topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab, successfully met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint, overall survival (OS). HARMONi is a multiregional, double-blinded, placebo-controlled, Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials in showing either a PFS or OS benefit.

Modular Medical, Inc. (NASDAQ: MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

On June 16, Modular Medical announced its participation in the American Diabetes Association (“ADA”) 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. The Company will feature a poster, number 783-P, titled “Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse,” to be presented by David Maggs, MD, FRCP during the General Poster Session on Sunday, June 22, 2025, from 12:30pm to 1:30pm in the Poster Hall. The presentation will highlight data from an exploratory study evaluating the effects of pump-delivery of a short-acting GLP-1RA on weight, food intake, and glucose tolerance in a diet-induced obese (“DIO”) mouse.”We are excited to share our findings from this novel study in the DIO mouse comparing the pump delivery of exenatide to intermittent dosing of semaglutide,” said Jeb Besser, CEO of Modular Medical. “Given the high rate of gastrointestinal tolerability challenges and resultant discontinuation that is characteristic of GLP-1 therapy, we believe that a personalized approach to GLP-1 titration and dosing, including a mealtime bolus option, would give patients an opportunity to reach their treatment goals, while experiencing easier therapy initiation and a more tolerable maintenance regimen.”

After the close May 28, Modular Medical announced the appointment of Jeff Goldberg to its Board of Directors. Mr. Goldberg brings decades of experience in health care, life sciences, and medical device leadership, including development of generic insulin. Mr. Goldberg began his work in medical technology alongside pioneering medical entrepreneur, and founder of MiniMed, Alfred E. Mann. Mr. Goldberg currently serves as Chairman of Lannett Company, Inc., a generic pharmaceutical manufacturer where he has helped execute a post-restructuring turnaround. During his tenure, Lannett has made significant strides in launching a generic insulin product – progress that aligns closely with Modular Medical’s commitment to innovation and affordability in diabetes care. In addition to his work at Lannett, Mr. Goldberg previously served as President and CEO within Alfred E. Mann’s incubator, IncuMed, where he oversaw multiple portfolio companies focused on drug-device combination products, including an insulin patch-pump program. His tenure with Mr. Mann’s enterprises included pivotal roles in regulatory strategy, operations turnaround, and successful exits, underscoring his ability to guide early-stage technologies to commercial viability. Mr. Goldberg also serves on the boards of several health-care and consumer-focused companies, including ATI Physical Therapy, Cano Health, and Eating Recovery Centers. He holds a JD from UCLA School of Law and an AB from Harvard College. Mr. Goldberg stated, “Modular Medical is advancing a truly disruptive approach to insulin delivery. I’m excited to join the board and contribute to the Company’s journey toward simplifying treatment for people living with diabetes, particularly as the industry shifts toward more accessible and patient-friendly solutions.”

Jeb Besser, CEO of Modular Medical, presented on May 29 at Tribe Public’s Webinar Presentation and Q&A Event titled“Making Diabetes Management Simpler: The New Era of Insulin Therapy.”You may view the event video now at the Tribe Public YouTube Channel.

Shares of ADT Inc. (ADT) is a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada.

ADT released Q1, 2025 results on Thursday, April 24 and highlighted the following: Continued strong financial results with record recurring monthly revenue and customer retention, GAAP operating cash flows up 28%, Adjusted Free Cash Flow including interest rate swaps up 105%, Returned $445 million to shareholders through share repurchases and dividends, and that they are on track to achieve full year 2025 guidance metrics.

On April 30, ADT in collaboration with Yale and the Z-Wave Alliance, announced the launch of the Yale Assure Lock 2 Touch with Z-Wave for ADT+. The Z-Wave 800 Series smart lock is the only one on the market with fingerprint control and the first smart lock to leverage the newly introduced Z-Wave User Credential Command Class. This industry-first innovation allows users to unlock and disarm their ADT+ security system using just their fingerprint.

On Jan. 22, ADT announced the appointment of Thomas Gartland to the Company’s Board of Directors as an additional independent director. In conjunction with his appointment, Gartland will join the Board’s Audit Committee. Gartland is chairman and chief executive officer of Montway Auto Transport, a privately held auto transport company, and has held this position since 2023. Prior to Montway, Gartland served as executive chairman of Scan Global Logistics and as president, North America, for Avis Budget Group. Gartland serves on the boards of Xenia Hotels & Resorts, Inc. and ABM.

GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases.

On July 3, GeoVax emphasized the urgent need for innovation in COVID-19 vaccination as the NB.1.8.1 variant – commonly known as “Nimbus” – spreads rapidly across the globe. Nimbus, a highly transmissible Omicron subvariant classified by the World Health Organization as a “Variant Under Monitoring,” is now dominant in multiple U.S. states and surging across Europe and Asia. Though not more severe, its rapid spread and potential for immune escape reflect an increasingly clear reality: COVID-19 is not going away, and it will continue to evolve.

On July 2, GeoVax emphasized the growing global public health importance of its GEO-MVA Mpox/smallpox vaccine in response to rising public health threats and a rapidly evolving regulatory environment. With favorable regulatory input from the European Medicines Agency (EMA), GEO-MVA is on an expedited path toward market access, accelerating GeoVax’s focus toward regulatory approval and commercialization. “GeoVax is entering a value inflection phase,” said David Dodd, Chairman and CEO. “The EMA’s expedited development path brings us closer to regulatory registration and commercial readiness, providing the opportunity to address urgent public health needs, expanding the critically needed supply option of MVA-vaccine, addressing both expanding outbreak needs and stockpile opportunities.”

On July 1, GeoVax Labs announced that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 9.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.65 per unit in a public offering. The Company will issue warrants to purchase up to approximately 18.5 million shares of common stock. The warrants will have an exercise price of $0.65 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about July 2, 2025, subject to the satisfaction of customary closing conditions.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases.

On July 1, Indaptus announced the additional sale of approximately $3.4 million in aggregate principal amount of convertible promissory notes and accompanying warrants. Together with a prior sale of $2.3 million of convertible promissory notes and accompanying warrants, the Company raised an aggregate of $5.7 million in gross proceeds in this offering.

On June 2, Indaptus announced that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne’s (formerly known as Beigene) PD-1 checkpoint inhibitor, tislelizumab. This newly activated arm of the trial will assess safety, dose optimization, and early signs of anti-tumor activity in patients with advanced solid tumors, previously treated with a checkpoint inhibitor or with tumors typically unresponsive to a checkpoint inhibitor. Jeffrey Meckler, Indaptus’ CEO commented, “This is an important milestone in our clinical development. We have long believed the Decoy platform has the potential to be a game-changing approach to treating solid tumors. Preclinical data consistently demonstrated that Decoy20 works synergistically with a checkpoint inhibitor. Now, for the first time, we are testing this combination in patients. Checkpoint inhibitors, like tislelizumab, have been one of the biggest breakthroughs in cancer therapy and have significantly improved outcomes in a variety of cancers. However, most patients still do not benefit. We believe the combination of Decoy20 plus a PD-1 inhibitor, such as tislelizumab, could enhance immune responses, potentially helping patients who have not responded or have tumors that classically do not respond to checkpoint inhibitor therapy.”

Teladoc Health (TDOC) is the world leader in virtual care. Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.

Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Serina’s definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina’s 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), for inclusion in Serina’ proxy materials for the Annual Meeting will be 5:00 p.m. (Central Time) on Friday, August 15, 2025, which Serina’s Board of Directors has determined to be a reasonable period of time before Serina expects to begin to print and send its proxy materials for the Annual Meeting. Stockholder proposals submitted in accordance with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a-8 in order to be included in the proxy materials for the Annual Meeting. Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com.

Quote of the Day

“People only see what they are prepared to see.” – Ralph Waldo Emerson

Sources

Investing & Inspiration

“We cannot live only for ourselves. A thousand fibers connect us with our fellow men.” – Herman Melville

Post View Count : 501

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

We value your privacy and will never share your information.

Stocks Conclude The Week On A Softer Note Friday, July 11, 2025 – ( $BTC $MCD $NVDA $TSLA Rise!)

Vista Partners Watchlist Highlights & Updates

Quote of the Day

Investing & Inspiration

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

Recent Posts

VP Watchlist

Trending Posts

Stocks Conclude The Week On A Softer Note Friday, July 11, 2025 – ( $BTC $MCD $NVDA $TSLA Rise!)

Macroeconomic Reports

S&P 500, Dow 30, Nasdaq, and Russell Index Highlights

Noteworthy Company News

NVIDIA (NVDA)

Tesla (TSLA)

Meta Platforms (META)

McDonald’s (MCD)

Oracle (ORCL)

Palantir Technologies (PLTR)

Rio Tinto Group (RIO)

Corporate Actions: Acquisitions, Mergers, and IPOs

Tariffs, Yield Curve, and Interest Rates

FOMC Announcements

Commodities and Cryptocurrency Closing Prices

Vista Partners Watchlist Highlights & Updates

Quote of the Day

Investing & Inspiration

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

Recent Posts

VP Watchlist

Trending Posts